Form 8-K - Current report:
SEC Accession No. 0001628280-26-009805
Filing Date
2026-02-19
Accepted
2026-02-19 16:31:34
Documents
13
Period of Report
2026-02-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20260218.htm   iXBRL 8-K 60454
2 EX-10.1 vndaex1018-k2192026.htm EX-10.1 33698
  Complete submission text file 0001628280-26-009805.txt   222726

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20260218.xsd EX-101.SCH 1834
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20260218_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20260218_pre.xml EX-101.PRE 13084
15 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20260218_htm.xml XML 2834
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 26654944
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)